Table 2 Mutation profile of study patients.

From: Validation of the IPSET score for thrombosis in patients with prefibrotic myelofibrosis

Variables

N

 

Driver mutation

  

JAK2V617F, n (%)

378

246 (65)

VAF

225

36.8 (0.3–100)

CALR type1, n (%)

288

63 (22)

VAF

44

50 (9–63.7)

CALR type2, n (%)

134

24 (18)

VAF

21

49 (7–94)

MPL W515x, n (%)

336

17 (5)

Triple negatives, n (%)

377

31 (8)

Non-driver mutations

  

ASXL1, n (%)

133

28 (21)

EZH2, n (%)

132

5 (4)

SRSF2, n (%)

132

14 (11)

IDH1/2, n (%)

132

1 (1)

HMR, n (%)

132

37 (28)

HMR ≥ 2, n (%)

132

11 (8)

  1. Data are reported as median (range).
  2. VAF variant allele frequency, HMR high molecular risk, points to the presence of at least one mutation in any one of ASXL1, EZH2, SRSF2, IDH1/2. HMR ≥ 2 means the presence of two or more mutated genes among the above. Two or more mutations in the same gene are counted as one.
Back to article page